Financial Performance - Quanterix Q4 2019 revenue reached $15.9 million, a 46% increase compared to $10.9 million in Q4 2018[7, 79] - Full year 2019 revenue was $56.7 million, representing a 51% growth from $37.6 million in 2018[7, 79] - Consumables revenue showed significant growth, with full year 2019 consumables revenue increasing by 86%[6, 7] - Adjusted gross margin for full year 2019 was 49.7%, an increase of 380 bps compared to 45.9% in 2018[7] Product and Market Growth - Instruments revenue grew by 55% for the full year 2019[7, 9] - Neurology showed a growth of 121%[10] - The company raised approximately $120 million in growth capital[6] Technology and Innovation - Simoa technology enables a +3,000X increase in sensitivity[18] - The company aims for a 100x sensitivity increase by the end of 2021[62] - Nf-L publications increased significantly, demonstrating clinical utility in disease activity monitoring and drug efficacy[6, 44] Strategic Focus - The company is focused on neurology and oncology, with strategic mergers and acquisitions to expand capabilities[6, 62] - Quanterix has a methodical market penetration strategy targeting both research and diagnostics markets, with an aspiration to disrupt the $40B+ diagnostics market[25, 27, 67] - The company aims to achieve 50%+ utilization and 50% HD-X installed base by the end of 2020[62]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2019 For the transition period from to . Commission File Number: 001‑38319 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 20‑8957988 (St ...

[PART I — FINANCIAL INFORMATION](index=4&type=section&id=PART%20I%20%E2%80%94%20FINANCIAL%20INFORMATION) This section presents the company's financial statements, management's analysis, and related disclosures [Special Note Regarding Forward-Looking Statements](index=3&type=section&id=Special%20Note%20Regarding%20Forward-Looking%20Statements) This section warns investors that forward-looking statements are subject to risks and uncertainties, and actual results may differ materially - The report includes forward-looking statements concerning financial performance subject to **risks and uncertainties**[8](index=8&type=chunk) - The company disclaims any obligation to update forward-looking statements, advising against undue reliance on them as future predictions[9](index=9&type=chunk) [Financial Statements](index=4&type=section&id=Item%201.%20Financial%20Statements) This section presents unaudited condensed consolidated financial statements, highlighting asset growth, revenue increase, and a wider net loss [Unaudited Condensed Consolidated Balance Sheets](index=4&type=section&id=Unaudited%20Condensed%20Consolidated%20Balance%20Sheets) This section details the company's financial position, presenting assets, liabilities, and equity at specific dates Condensed Consolidated Balance Sheet Highlights (in thousands) | Account | June 30, 2019 | December 31, 2018 | | :--- | :--- | :--- | | **Assets** | | | | Cash and cash equivalents | $72,025 | $44,429 | | Total current assets | $92,386 | $59,496 | | Total assets | $109,408 | $67,611 | | **Liabilities & Equity** | | | | Total current liabilities | $17,018 | $18,125 | | Total liabilities | $34,663 | $26,546 | | Total stockholders' equity | $74,745 | $41,065 | | Total liabilities and stockholders' equity | $109,408 | $67,611 | - **Total assets** significantly increased to **$109.4 million** from **$67.6 million**, driven by cash and cash equivalents[13](index=13&type=chunk) - **Total stockholders' equity** grew to **$74.7 million** from **$41.1 million**, primarily from an at-the-market stock offering[13](index=13&type=chunk) [Unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss](index=5&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Operations%20and%20Comprehensive%20Loss) This section outlines the company's financial performance, including revenue, expenses, and net loss over specific periods Statement of Operations Summary (in thousands, except per share data) | Metric | Q2 2019 | Q2 2018 | YTD 2019 | YTD 2018 | | :--- | :--- | :--- | :--- | :--- | | Total revenue | $13,536 | $8,643 | $25,872 | $16,164 | | Gross profit | $6,931 | $3,973 | $12,936 | $7,145 | | Loss from operations | $(10,514) | $(7,311) | $(19,873) | $(14,475) | | Net loss | $(10,563) | $(7,343) | $(19,968) | $(14,545) | | Net loss per share | $(0.46) | $(0.34) | $(0.88) | $(0.67) | - Total revenue for Q2 2019 increased by **56.6% year-over-year**, driven by a **68.8% increase in product revenue**[14](index=14&type=chunk) - Net loss widened in Q2 2019 to **$10.6 million** from **$7.3 million** in Q2 2018, primarily due to increased Selling, General and Administrative expenses[14](index=14&type=chunk) [Unaudited Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Unaudited%20Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) This section reports the company's cash inflows and outflows from operating, investing, and financing activities Condensed Consolidated Statements of Cash Flows (in thousands) | Activity | Six Months Ended June 30, 2019 | Six Months Ended June 30, 2018 | | :--- | :--- | :--- | | Net cash used in operating activities | $(12,820) | $(13,970) | | Net cash used in investing activities | $(9,830) | $(3,691) | | Net cash provided by (used in) financing activities | $50,272 | $(1,547) | | Net increase (decrease) in cash | $27,622 | $(19,208) | - Net cash provided by financing activities was **$50.3 million** for the first six months of 2019, primarily due to **$48.0 million** in net proceeds from an at-the-market offering[18](index=18&type=chunk) - Net cash used in investing activities increased to **$9.8 million**, mainly from purchases of property and equipment, compared to **$3.7 million** in the prior year period which included an acquisition[18](index=18&type=chunk) [Unaudited Consolidated Statements of Stockholders' Equity](index=7&type=section&id=Unaudited%20Consolidated%20Statements%20of%20Stockholders'%20Equity) This section details changes in the company's equity, including stock issuances and the impact of net loss - Stockholders' equity increased from **$41.1 million** at December 31, 2018, to **$74.7 million** at June 30, 2019[20](index=20&type=chunk) - The increase in equity was primarily driven by the sale of common stock in an at-the-market offering, which raised **$48.0 million** in net proceeds, offset by a net loss of **$20.0 million** for the six-month period[20](index=20&type=chunk) [Notes to Condensed Consolidated Financial Statements](index=9&type=section&id=Notes%20to%20Condensed%20Consolidated%20Financial%20Statements) This section provides detailed explanations and disclosures supporting the condensed consolidated financial statements - The company develops and markets ultra-sensitive digital immunoassay platforms (Simoa) for life sciences research and diagnostics, launching its third instrument, the SP-X, in April 2019[23](index=23&type=chunk)[24](index=24&type=chunk) - On January 1, 2019, the company adopted the new revenue recognition standard ASC 606 using the modified retrospective method, resulting in a **$0.4 million** adjustment to accumulated deficit[36](index=36&type=chunk)[37](index=37&type=chunk) - Subsequent to the quarter end, on August 1, 2019, the company completed the acquisition of UmanDiagnostics AB for an aggregate price of **$22.5 million**, consisting of **$16.0 million** in cash and **$6.5 million** in common stock[111](index=111&type=chunk) - On June 5, 2019, the company issued approximately **2.2 million shares** of common stock through an at-the-market offering, resulting in net proceeds of **$48.0 million**[28](index=28&type=chunk)[107](index=107&type=chunk) [Management's Discussion and Analysis of Financial Condition and Results of Operations](index=34&type=section&id=Item%202.%20Management's%20Discussion%20and%20Analysis%20of%20Financial%20Condition%20and%20Results%20of%20Operations) Management discusses financial performance, noting revenue growth, improved gross margin, increased operating expenses, and strengthened liquidity Q2 2019 vs Q2 2018 Results (in thousands) | Metric | Q2 2019 | Q2 2018 | $ Change | % Change | | :--- | :--- | :--- | :--- | :--- | | Total Revenue | $13,536 | $8,643 | $4,893 | 56.6% | | Gross Profit | $6,931 | $3,973 | $2,958 | 74.5% | | R&D Expense | $4,016 | $3,705 | $311 | 8.4% | | SG&A Expense | $13,429 | $7,579 | $5,850 | 77.2% | | Net Loss | $(10,563) | $(7,343) | $(3,220) | 43.9% | - The **56.6% revenue increase** in Q2 2019 was driven by higher instrument sales (**$2.7 million** vs **$1.8 million**) and consumables sales (**$6.1 million** vs **$3.4 million**), reflecting a growing installed base[127](index=127&type=chunk)[129](index=129&type=chunk) - The **77.2% increase in SG&A expense** in Q2 2019 was primarily due to headcount additions, public company costs, a new headquarters lease, and approximately **$0.9 million** in costs associated with the Uman acquisition[133](index=133&type=chunk) - The company raised **$48.0 million** in net proceeds from an at-the-market stock offering during the second quarter of 2019, significantly bolstering its cash position[145](index=145&type=chunk) [Quantitative and Qualitative Disclosures About Market Risk](index=47&type=section&id=Item%203.%20Quantitative%20and%20Qualitative%20Disclosures%20About%20Market%20Risk) This section confirms no material changes to the market risk information previously disclosed in the 2018 Annual Report on Form 10-K - There were no material changes to the company's market risk disclosures from those reported in the 2018 Annual Report on Form 10-K[176](index=176&type=chunk) [Controls and Procedures](index=47&type=section&id=Item%204.%20Controls%20and%20Procedures) Management concluded disclosure controls and procedures were effective, with no material changes to internal control over financial reporting during the quarter - The company's principal executive officer and principal financial officer concluded that disclosure controls and procedures were effective as of June 30, 2019[177](index=177&type=chunk)[178](index=178&type=chunk) - There were no material changes to the company's internal control over financial reporting during the second quarter of 2019[179](index=179&type=chunk) [PART II — OTHER INFORMATION](index=49&type=section&id=PART%20II%20%E2%80%94%20OTHER%20INFORMATION) This section covers legal proceedings, risk factors, equity sales, and other miscellaneous disclosures [Legal Proceedings](index=49&type=section&id=Item%201.%20Legal%20Proceedings) The company reports it is not currently a party to any material legal proceedings - As of the filing date, the company is not involved in any material legal proceedings[182](index=182&type=chunk) [Risk Factors](index=49&type=section&id=Item%201A.%20Risk%20Factors) New risk factors relate to the UmanDiagnostics AB acquisition, including integration challenges and failure to realize anticipated benefits - New risk factors have been added related to the acquisition of Uman[183](index=183&type=chunk) - Key risks include the potential failure to realize anticipated benefits and cost savings from the Uman acquisition and the possibility of business disruption during the integration process[183](index=183&type=chunk) - The company notes that managing the expanded operations post-acquisition presents challenges, and failure to do so effectively could adversely impact future results[184](index=184&type=chunk) [Unregistered Sales of Equity Securities and Use of Proceeds](index=49&type=section&id=Item%202.%20Unregistered%20Sales%20of%20Equity%20Securities%20and%20Use%20of%20Proceeds) This section confirms no unregistered equity sales and updates on the use of IPO proceeds for operations, investments, and acquisitions - The company completed its IPO on December 11, 2017, receiving net proceeds of approximately **$65.6 million**[186](index=186&type=chunk)[187](index=187&type=chunk) - As of June 30, 2019, approximately **$54.3 million** of the IPO proceeds have been used for operating expenses, capital investments, debt payments, and the Aushon acquisition[187](index=187&type=chunk)[188](index=188&type=chunk) [Defaults Upon Senior Securities](index=51&type=section&id=Item%203.%20Defaults%20Upon%20Senior%20Securities) This item is not applicable as the company has not defaulted upon any senior securities - Not applicable[191](index=191&type=chunk) [Mine Safety Disclosures](index=51&type=section&id=Item%204.%20Mine%20Safety%20Disclosures) This item is not applicable to the company's operations - Not applicable[192](index=192&type=chunk) [Other Information](index=51&type=section&id=Item%205.%20Other%20Information) The company reports no other information for this item - Not applicable[193](index=193&type=chunk) [Exhibits](index=51&type=section&id=Item%206.%20Exhibits) This section lists exhibits filed with the Form 10-Q, including agreements, officer certifications, and XBRL data files - A list of exhibits filed with the Form 10-Q is provided, including the Share Purchase Agreement for Uman, an amendment to a loan agreement, and certifications by the CEO and CFO[194](index=194&type=chunk)[195](index=195&type=chunk)

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number: 001-38319 QUANTERIX CORPORATION (Exact name of registrant as specified in its charter) Delaware 20-8957988 (State or other jurisd ...

Use these links to rapidly review the document TABLE OF CONTENTS TABLE OF CONTENTS 2 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 02421 (Zip Code) o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to MA (Address of principal executive offices) Commission file number: 001-38319 QUANTERIX ...